Dr. Rick Shinto Leading InnovaCare Health towards Further Success

As a company, InnovaCare Health is known for their strong company values, excellent teamwork and leadership, and high quality products. This company is a provider of physician practice services and Medicare Advantage plans. The company has two affiliate programs called MM Healthcare Inc and PMC Medicare Choice Inc. Both extensions of InnovaCare rise to the same high quality of InnovaCare Health, and have a 90 percent rate of customer satisfaction. This speaks volumes about the quality of the plans that InnovaCare Health implements.

One of the strong forces of leadership within the InnovaCare Health business is Dr. Rick Shinto. Rick Shinto became CEO of the InnovaCare team in 2012, and since then has become known as a source of inspiration for the company. He brought with him many years of experience in the healthcare field. Learn more about Rick on XRepublic.

Dr. Rick Shinto received his undergraduate bachelors of science from the University of California, and then went on to study medicine at the University of New York. He also earned a master’s in business at the University of Redlands, which prepared him for the dual role of health care expert and business CEO. Dr. Shinto started his medical practice as a pulmonologist in California. He became the Chief Medical officer of North American Medical Management (NAMM) also while he was in California. His recognized skills as a leader in the field of business and healthcare propelled him into the position of CEO of Aveta Inc. While working with Aveta, Dr. Shinto was honored with a prestigious award for entrepreneurs who display innovative actions, and community beneficence. The award, called the “Ernst & Young Entrepreneur of the Year Award” was a fitting recognition of the hard work that he was putting in with the Aveta Inc. community.

After Aveta, Dr. Rick Shinto began work with InnovaCare Health, and is now using his visionary abilities and strong values to lead the company towards further success. Under Dr. Shinto’s leadership, the team has expanded their reach in order to help more people. The companies that they have set up in PuertoRico are one example of this. Through technology they are able to offer higher quality care plans with no additional cost for residents, making it a helpful addition in many people’s lives. One of the InnovaCare Health model’s goals is to improve patients’ health through providing access to care providers that are high quality. The care plans combine mental and physical wellness into the coverage. For the average person, a visit to a doctor’s office can be affordable rather than a stressful experience, and this has made a positive difference in many people’s lives. Read this article at openminds.com

The Reality of Anti-Aging Drug and the Influence of Dr. Mikhail Blagosklonny

Dr. Mikhail Blagosklonny, an oncologist and researcher, known for making a significant influence in anti-ageing drug development. As a scientist in aging and cancer, he formulated hyperfunction theory that changed the concept of aging in the early 2000’s. It was previously believed that the aging was the functional decline due to the molecular damage, and it cannot be prevented. The theory put forward by Blagosklonny stated that aging is just a continuation of growth that is driven by some sort of signaling pathways such as Target of Rapamycin (TOR). The theory paved ways for further research on anti-aging drugs with the initial development of Everolimus, a rapamycin analog, in 2008. After more than six years of experiments, the analog shows improvements in the immunity of old humans, as predicted by Dr. Blagosklonny.

The TOR-centric model suggested that rapamycin and other rapalogs could be used for treating aging and preventing diseases. It further said that with proper schedules and doses, rapamycin would extend the healthier lifespan of humans. Though the critics ridiculed the theory initially, now, they are forced to accept the effectiveness of TOR-centric model with the proven results. Currently, many of the pharmaceutical firms are chasing down the rapamycin analogs, and Novartis confirmed that it is in the works of developing a ‘Fountain of Youth’ Drug” that can delay the effects of aging. Visit classroomvoices.org to read more about Mikhail.

The hyperfunction theory suggested the calorie-restriction-mimicking characteristic and side-effects of rapalogs in the initial days. For instance, rapamycin increases lipolysis to imitate fasting. Additionally, it can cause “starvation diabetes” in some cases that creates glucose intolerance and insulin resistance. This induced state can stop the complications of type II diabetes. The MTOR-centric model proposed that the restorable insulin resistance can cause increased longevity as the longevity is promoted by the decreased mTOR signaling. The TOR-centric model identified that the growth-promoting signaling at the initial years of growth is becoming harmful in the later part of the life and cause aging. Dr. Blagosklonny also confirmed three sources of the TOR-centric model, which is the genetics of longevity, cellular senescence, and diseases.

Dr. Blagosklonny is a professor of Oncology at the reputed Roswell Park Cancer Institute with research on cancer and aging. He started his career with New York Medical College as an associate professor of medicine. Later, Dr. Blagosklonny moved to Ordway Research Institute and served there as a senior scientist. In 2009, he joined Roswell Park with research interests in Biogerontology, anti-aging drugs, targeted cancer therapies, and more.

Follow: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531

Dr. Blagosklonny is closely associated with many medical journals. He is the editor-in-chief of Cell Cycle and Oncotarget. Dr. Mikhail Blagosklonny is also working on cancer biology and therapy, PLOS ONE, International Journal of Cancer, and the American Journal of Pathology as their associate editor and serves on the editorial board of Cell Death and Differentiation. He has published more than 300 research papers, reviews, and book chapters. Dr. Blagosklonny earned his medical graduation from the First Pavlov State Medical University and later completed his M.D. in Internal Medicine. He also did a Ph.D. in Cardiology and Experimental Medicine from the same university.